Abrilumab - Amgen/AstraZeneca

Drug Profile

Abrilumab - Amgen/AstraZeneca

Alternative Names: Abrilimumab; AMG-181; Anti-α4β7 integrin monoclonal antibody; MEDI-7183

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 10 Apr 2018 AstraZeneca completes a phase II trial for Ulcerative colitis in Japan (SC) (NCT01959165)
  • 10 Apr 2018 Amgen completes a phase II trial for Ulcerative colitis in USA, Canada, Australia, United Kingdom, Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Netherlands, Poland, Norway, Switzerland and Russia (SC) (NCT01694485)
  • 10 Apr 2018 Amgen completes a phase II trial for Crohn's disease in USA, Canada, European Union and Switzerland (NCT01696396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top